Study pinpoints anti-HPA-1a antibodies that may raise FNAIT risk
Certain anti-HPA-1a antibodies can cause platelet aggregation through the FcγRIIa receptor, a mechanism that may contribute to FNAIT.
Certain anti-HPA-1a antibodies can cause platelet aggregation through the FcγRIIa receptor, a mechanism that may contribute to FNAIT.
Learn more about the role and function of the spleen, which is a major site of platelet destruction, in FNAIT.
Researchers developed a three-dimensional model to study the mechanisms behind intraventricular hemorrhage.
A woman who experienced a miscarriage did not respond to several platelet transfusions due to the presence of anti-platelet antibodies.
Interviews of patients affected by FNAIT revealed diagnostic challenges and strained relationships with healthcare providers.
A study found that anti-HLA antibodies can trigger mild thrombocytopenia in mice, but their ability to cause FNAIT is uncertain.
Find out how platelet transfusions for FNAIT are different from those used to treat other bleeding disorders.
Researchers developed a statistical model that could help clinicians make platelet transfusion decisions for infants with thrombocytopenia.
Learn more about the difference between FNAIT caused by HPA-5b versus HPA-1a antibodies, including prevalence, disease severity and more.
A recent study found that a minimally invasive neurosurgical procedure can treat intraventricular hemorrhage (IVH), a complication of FNAIT.